Skip to main content

Table 3 Medical history ongoing at baseline (MITT/cIAI population and mMITT/cUTI population)

From: Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

System organ class, n (%)a

Diabetes

No diabetes

Differenceb;

 Preferred term

n = 198

n = 1408

P value

Cardiac disorders

50 (25.3)

177 (12.6)

−12.7; <0.00001

 Coronary artery disorders

34 (17.2)

107 (7.6)

−9.6; <0.00001

 Heart failures

15 (7.6)

39 (2.8)

−4.8; 0.00045

Endocrine disorders

17 (8.6)

57 (4.0)

−4.5; 0.00436

 Hypothyroidism

14 (7.1)

41 (2.9)

−4.2; 0.00260

Eye disorders

14 (7.1)

33 (2.3)

−4.7; 0.00022

 Diabetic retinopathy

9 (4.5)

0

−4.5; <0.00001

Hepatobiliary disorders

21 (10.6)

82 (5.8)

−4.8; 0.01014

 Hepatic and hepatobiliary disorders

13 (6.6)

30 (2.1)

−4.4; 0.00030

Infections and infestations

55 (27.8)

228 (16.2)

−11.6; 0.00006

 Urinary tract infections

35 (17.7)

119 (8.5)

−9.2; 0.00004

 Viral infectious disorders

10 (5.1)

25 (1.8)

−3.3; 0.00313

Metabolism and nutrition disorders

198 (100.0)

166 (11.8)

−88.2; <0.00001

 Glucose metabolism disorders, including diabetes

198 (100.0)

16 (1.1)

−98.9; <0.00001

 Lipid metabolism disorders

31 (15.7)

62 (4.4)

−11.3; <0.00001

 Obesity

13 (6.6)

37 (2.6)

−3.9; 0.00282

Musculoskeletal and connective tissue disorders

32 (16.2)

114 (8.1)

−8.1; 0.00022

 Joint disorders

23 (11.6)

64 (4.5)

−7.1; 0.00004

Nervous system disorders

34 (17.2)

99 (7.0)

−10.1; <0.00001

 Peripheral neuropathies

17 (8.6)

1 (0.1)

−8.5; <0.00001

Psychiatric disorders

22 (11.1)

79 (5.6)

−5.5; 0.00284

 Depressive disorders

13 (6.6)

33 (2.3)

−4.2; 0.00086

Renal and urinary disorders

67 (33.8)

245 (17.4)

−16.4; <0.00001

 Chronic kidney disease

17 (8.6)

19 (1.3)

−7.2; <0.00001

 Diabetic nephropathy

12 (6.1)

0 (0.0)

−6.1; <0.00001

 Urolithiases

22 (11.1)

81 (5.8)

−5.4; 0.00397

Respiratory, thoracic, and mediastinal disorders

28 (14.1)

87 (6.2)

−8.0; 0.00005

 Bronchospasm and obstruction

17 (8.6)

49 (3.5)

−5.1; 0.0007

Vascular disorders

140 (70.7)

390 (27.7)

−43.0; <0.00001

 Hypertension

131 (66.2)

342 (24.3)

−41.9; <0.00001

  1. cIAI complicated intra-abdominal infection, cUTI complicated urinary tract infection, MITT microbiologic intention-to-treat, mMITT modified microbiologic intention-to-treat
  2. aOnly preferred terms with differences in rates between patients with and without diabetes are presented
  3. bPercentage difference calculated for patients with history of diabetes compared with those with no history of diabetes
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us